Ascentage Pharma presents preclinical data for 4 novel drug candidates at 2024 AACR Annual Meeting.
Ascentage Pharma presents results from three preclinical studies at the 2024 AACR Annual Meeting, showcasing novel drug candidates: olverembatinib, MDM2-p53 inhibitor alrizomadlin (APG-115), FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449, and EED inhibitor APG-5918. The company aims to support potential clinical development and therapeutic combinations for cancer, age-related diseases, and chronic hepatitis B.
April 08, 2024
3 Articles